ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%),...

|By:, SA News Editor

ImmunoGen (IMGN +1.8%) says it's amended its multi-target agreement with Novartis (NVS -0.6%), which was originally entered into in October, 2010. As a result, IMGN is eligible to receive a $1M upfront fee and the opportunity to receive milestone payments potentially totaling approximately $200M or $238M, depending on the composition of any resultant products.